Skip to main content
Premium Trial:

Request an Annual Quote

Biogen Idec, NHF Launch Hemophilia Genotype Testing Initiative

NEW YORK (GenomeWeb News) – Two patient advocacy groups, Biogen Idec, and a medical center have teamed up to offer free or low-cost genetic testing to people with hemophilia and their families to identify ways to personalize patient care, generate new genetic information, and help create a database for use in research.

The National Hemophilia Foundation said today that the project, called My Life, Our Future: Genotyping for Progress in Hemophilia, is aimed at providing useful genetic and clinical information to clinicians, researchers, and patients by removing the primary barrier to genetic testing — cost and insurance coverage.

Biogen Idec Hemophilia, a business unit of Biogen Idec focused on hemophilia, will provide the financial support for the initiative, as well as scientific advice and project management support, although the company will not receive special access to the data or samples involved.

The testing program will be made available through participating hemophilia treatment centers beginning in 2013. It initially will be offered to people with hemophilia A and B and over time will be expanded to potential carriers and their families.

Other partners involved in the project with NHF and Biogen Idec Hemophilia include the American Thrombosis and Hemostasis Network and the Puget Sound Blood Center.

NHF said that research has shown that some genetic mutations are associated with an increased risk for severe bleeding and inhibitors, major hemophilia treatment complications involving an immune system response. Testing can enable healthcare providers to tailor their treatments based on genotype, and women in a patient's family also may be tested for the gene for hemophilia and could receive genetic counseling for family planning and pregnancy care, NHF said.

Despite the possible benefits of genotyping for hemophilia patients, only around 20 percent of people with hemophilia in the US have been genotyped, although more than 75 percent of people responding to a recent survey expressed an interest in receiving testing, NHF said. According to that survey, cost and insurance coverage restrictions were the main reasons people gave for not getting tested.

“This partnership is about helping people affected by hemophilia gain a better understanding of their genetic make-up and working with healthcare providers to use that information to provide more individualized care tailored to the needs of families,” NHF CEO Val Bias said in a statement.

The Scan

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.

Study Reviews Family, Provider Responses to Rapid Whole-Genome Sequencing Follow-up

Investigators identified in the European Journal of Human Genetics variable follow-up practices after rapid whole-genome sequencing.

BMI-Related Variants Show Age-Related Stability in UK Biobank Participants

Researchers followed body mass index variant stability with genomic structural equation modeling and genome-wide association studies of 40- to 72-year olds in PLOS Genetics.

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.